Skip Navigation

Biometrika 2003 90(3):597-611; doi:10.1093/biomet/90.3.597
© 2003 by Biometrika Trust
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hall, W. J.
Right arrow Articles by Yakir, B.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Inference about a secondary process following a sequential trial

W.J. Hall1 and Benjamin Yakir2

1 Department of Biostatistics, University of Rochester, Rochester, New York 14642-8630, U.S.Ahall{at}bst.rochester.edu 2 Department of Statistics, The Hebrew University of Jerusalem, Jerusalem 91905, Israel.msby{at}mscc.huji.ac.il

We consider the following sequential testing problem.A group-sequential or fully-sequential test is carried out for a primary parameter, using a score process or an effective score process to eliminate nuisance parameters. After stopping, the possibility of additional parameters is considered, and appropriate tests and estimators are desired that recognise the sequential stopping rule. We formulate an asymptotic multi-dimensional Gaussian process form of such problems, and then construct tests and confidence procedures. Optimality conditions are given, and an example is summarised.

Key Words: Clinical trial; Gaussian process; Median-unbiased estimator; Testing for interaction; Unbiased test

Received June 2002. Revised December 2002


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BiometrikaHome page
T. L. Lai, M.-C. Shih, and Z. Su
Tests and confidence intervals for secondary endpoints in sequential clinical trials
Biometrika, December 1, 2009; 96(4): 903 - 915.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.